Biofrontera Inc. (BFRI) NASDAQ
1.03
+0.0758(+7.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.03
+0.0758(+7.94%)
Currency In USD
Address
120 Presidential Way
Woburn, MA 01801
United States of America (the)
Phone
781 245 1325
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
92
First IPO Date
October 29, 2021
| Name | Title | Pay | Year Born |
| Hermann Luebbert | Chief Executive Officer, President & Chairman | 687,482 | 1956 |
| George Jones | Chief Commercial Officer | 275,184 | 1973 |
| Eugene Frederick Leffler | Chief Financial Officer | 461,333 | 1985 |
| Jon Lyons | Vice President of Scientific & Medical Affairs | 0 | N/A |
| Daniel Hakansson | Senior Corporate Counsel | 0 | N/A |
| Erica F. Gates | VP of Finance & Principal Accounting Officer | 0 | N/A |
| Samantha Widdicombe | Senior Vice President of Sales & Strategic Accounts | 0 | N/A |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.